The prescription leaves the pharmacy in a small bag. Everything else travels separately: the exercises, the speech practice, the effort to keep moving, the appointment someone must arrange. For a person with Parkinson’s disease, those activities can belong to the same treatment plan. They rarely arrive as one product. Remepy’s wager begins in that gap between what medicine contains and what care requires.
- Hybridopa pairs levodopa with a therapeutic app for Parkinson’s disease.
- A short randomized pilot produced encouraging results; the treatment remains investigational.
- Remepy is pursuing pharma partnerships, with Phase III planned for Q4 2026.
The company calls the combination a Hybrid Drug. The name sounds futuristic; the underlying observation is familiar. Medication and rehabilitation already coexist. Remepy wants to package their relationship into something that can be developed, prescribed and commercialized together. A phone becomes a delivery system for structured interventions. The interesting question is whether that packaging produces a benefit substantial enough to earn its place in medicine.
A molecule with no molecular weight
Remepy’s other term of art is Digital Molecule. No chemist needs to update the periodic table. It means therapeutic software: protocols intended to influence biological processes through physical, cognitive and behavioral activity. The platform, as the company describes it, uses patient data and AI to personalize those interventions. That is a design ambition whose value must be demonstrated for each treatment.
Its scientific interests include neuroplasticity, sensory integration and the relationship between brain activity and immune function. The company measures more than whether someone enjoyed an app. Its research toolkit includes imaging, clinical scales and blood or saliva biomarkers. These measurements can help investigate mechanisms, although a changed biomarker and a meaningful improvement in someone’s life remain different kinds of evidence.
A 2025 paper in npj Digital Medicine studied 103 adults with subjective cognitive decline and heightened anxiety, assigning them to an app program or a waiting-list control. It reported psychological improvements and changes associated with neuroimmune function. That supplies part of the research background. It does not establish an Alzheimer’s treatment, nor does success in that population automatically travel to another disease.
The experiment earns its headline
For Parkinson’s, the lead program is Hybridopa: levodopa paired with a digital protocol. The published pilot randomized 42 people to DopApp or a placebo app for three weeks; clinical analyses included 39. Medication remained stable. The active intervention brought together movement, speech, psychological and navigation exercises, alongside walking. This was daily participation, rather than a download left to gather electronic dust.
In the analyzed groups, the total MDS-UPDRS score fell by an average 9.7 points with DopApp and 1.95 with placebo. Lower scores indicate improvement. The difference was statistically significant. Imaging findings also suggested changes in relevant brain connectivity. The paper appeared in Brain Communications in May 2026.
The study was small, short and conducted at one centre. It could not establish durability or isolate which ingredients produced the effect. Medication timing also needed tighter standardization. These are useful questions for the next experiment. A promising average over three weeks offers a reason to continue investigating; it leaves the long view unresolved.
The customer holding the prescription pad
For patients, the attraction is structured care delivered at home alongside medication. For pharmaceutical companies, the attraction includes a differentiated drug product and additional intellectual property. Remepy occupies the meeting point between these interests. Its stated commercial approach centers on co-development with pharma, with the resulting combination intended to travel through prescription channels.
In April 2026, it announced a collaboration with Merck KGaA, Darmstadt, Germany, initially focused on some US programs in a rare tumor area. The distinction in the name matters: this is the German science and technology company. The agreement explores an additional setting for the platform; it is not evidence that the Parkinson’s findings have already been reproduced in oncology.
Remepy argues that a combined prescription can place digital treatment within pharmaceutical development, commercialization and reimbursement. Compared with a standalone health app, that is a consequential choice of customer and route to market. Reimbursement remains something to secure. The alternative for a patient today includes medication accompanied by separately organized physiotherapy, speech therapy and other care.
The money buys a longer question
The founding team spans software and neuroscience. Michal Tsur, previously a co-founder of Cyota and Kaltura, leads alongside co-CEO Or Shoval. Amir Amedi serves as chief scientific officer; Eran Etam is chief technology officer. The company’s own account of its culture puts weekly research sessions beside design sprints. One imagines the calendar has little respect for disciplinary boundaries.
A $10 million seed round announced in May 2024 brought reported funding at the time to $15 million. In August 2026, Remepy announced a $36 million Series A led by O.G. Venture Partners and M Ventures, reporting $62 million raised altogether. Funding is the scale of the wager, rather than a receipt for a particular trial or a patient’s eventual treatment bill.
The new capital is intended to expand partnerships and fund global Phase III development of Hybridopa, planned for Q4 2026. In September, Remepy appointed Eran Harary as chief medical officer. The near-term task is therefore clinical execution. Hybridopa remains investigational and is not FDA approved; readers can follow trial updates through the company’s community page.
Borrow the test, not the trademark
The transferable lesson is methodological. Pick a specific problem, hold the background treatment steady, give the comparison group a credible experience and measure something that matters. Remepy’s approach also asks product builders to consider distribution early: who prescribes, who pays and what evidence that system expects. Those questions belong in the design brief.
“Our mission is to improve patient outcomes.”Or Shoval / public seed-funding announcement, 2024
For Remepy, the phone is only useful if people can participate and the improvement survives a more demanding test. A program that requires daily activity must work in ordinary lives, beyond a closely followed pilot. The prescription bag is still small. The proposed change is to give the treatment inside it a longer reach.